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responses. As a result, many of these proteins have been explored for their potential as
diagnostic and vaccine candidates. Of these, the Antigen 85 complex proteins, represented
by Antigen85 A, B, and C, are the most studied from the mycobacterial secretome. However,
vaccine constructs exploiting Antigen 85 as the sole antigen repertoire have not experienced
the pre-clinical and clinical trials success originally anticipated. Anecdotal and biochemical
evidence suggests that differences in protein abundance may explain this phenomenon.
Here, biochemical, molecular, and mass spectrometry approaches were used to quantify
Antigen 85 among six M. tuberculosis strains from four phylogenetically distinct clades. Our
data demonstrates that the greatest variation in Antigen 85 is ascribed to protein quantities,
whereas few transcriptional differenceswere found. In addition, the ratio of Antigen 85A, to B,
to C is conserved within clades and phylogenetic neighbors. In contrast, no such relationship
between individual protein quantities was observed, and in the case of Antigen85 B, this
variation even extends within biological replicates of individual isolates. The relevance of
Antigen 85 protein quantities and vaccine efficacy remains to be defined.
Biological significance
Absolute quantitation via multiple reaction monitoring mass spectrometry was used to
determine the exactmolar concentrations of Antigen 85A, B, andC; three key immunodominant
proteins present in M. tuberculosis. Further, the concentration of these three proteins was
compared among various clades ofM. tuberculosis, and demonstrated differences in abundance
of two of the three proteins. These proteins have been identified as key antigens in multiple
vaccine and diagnostic platforms, thus the potential relevance of their abundance in various
M. tuberculosis clades to the successful outcome of these interventions is discussed.
This article is part of a Special Issue entitled: Trends in Microbial Proteomics.
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Mycobacterium tuberculosis (Mtb) is a deadly human pathogen
estimated to have infected one-third of the global population
and responsible for over 1.5 million deaths annually [1].
Exacerbated by the emergence of multi- and extensively drug
resistant bacteria, the need for diagnostic biomarkers, innova-
tive chemotherapeutic targets, and vaccine candidates–either
to replace or boost the current Bacille Calmette–Guérin (BCG)
vaccine–has never been greater.
The secreted or culture filtrate proteins (CFPs) ofMtb serve as
an antigenic reservoir from which the most potent candidates
destined for vaccine and biomarker development were first
characterized [2–6]. Included in this category are the Antigen 85
complex proteins (Rv3804c/FbpA/Ag85A, Rv1886c/FbpB/Ag85B
and Rv0129c/FbpC/Ag85C). The three homologous members of
the Antigen 85 complex (Ag85) contain mycolyltransferase
enzymatic activity key to the production of the lipid trehalose
dimycolate (TDM) and have beenwell studied for their potential
as drug targets [7]. In addition, all three proteins demonstrate a
capacity for binding a C-terminal motif of the human fibronec-
tin protein [8] and are believed to play a role in pathogenesis
[9,10]. Since its description by Wiker et al in 1986 [11], this
complex has been shown to be produced by all mycobacteria
regardless of their pathogenicity [12]. As demonstrated in
most essential genes and T cell antigens, Ag85 displays
minimal levels of polymorphisms and epitope variation
across lineages of the Mtb complex [13]. This phenomenon
highlights these proteins as both attractive vaccine compo-
nents and biomarkers.
The potential of these proteins as diagnostic and vaccine
candidates has been the impetus for detailed characteriza-
tion of both the enzymatic and immunological aspects of
these proteins. Each of these proteins can be readily purified
from the culture filtrate [7], due to their high concentration in
this secreted fraction, solubility, and stability in filtrates over
time [12,14,15]. The physiochemical properties of the Antigen
85 complex proteins has led to their production as recombi-
nant antigens retaining their enzymatic activity and allowing
elucidation of their crystal structures [16,17], as well as their
use in recombinant vaccines. Notably, Ag85A is the basis for a
modified vaccinia virus vaccine which has been found to be
safe in infants [18] and is in phase IIB clinical trials [19,20].
Likewise, an adenoviral vaccine containing both Ag85A and
Ag85B is in phase IIB clinical trials [19,20]. In addition, subunit
vaccines SSI/SP H4-IC31and SSI H56-IC31, both containing
Ag85B, and a recombinant BCG vaccine, which overexpresses
Ag85B [21], have been shown to be effective and safe in
pre-clinical trials and are currently in Phase I clinical trials
[19,20].
Recent papers suggest that while these proteins are con-
served across mycobacterial lineages, their abundance may
vary among strains of Mtb. Pheiffer and colleagues originally
noted qualitative differences in Ag85 relative abundance by
immunodetection [22], and expanded on these studies using
Western blotting and 2 dimensional gel electrophoresis (2DGE)
to demonstrate decreased abundance in Antigen 85 A, B and C,
and Antigen 85 A and C in Beijing and F23 isolates, respectively,
when compared to H37Rv [23]. Similarly, our laboratory used2DGE and mass spectrometry to demonstrate variability of
abundance of Ag85 in CDC1551 vs two closely related isolates
[24].
The differences reported for Ag85 abundance contrasts
with reports of low genomic and epitope variability among
strains [13] and prompted us to take a more quantitative
approach towards understanding the presence of these
proteins in the CFP from various clades of Mtb. Disparities in
the secretome of each lineage may play a vital role in
subsequent host responses driven by natural or vaccine-
induced immunity. Further, a quantitative assessment of
their variation should be considered in bacterial biomarker
selection.2. Methods
2.1. Bacterial culture and preparation of culture filtrate
proteins (CFPs)
Glycerol stocks of H37Rv, CDC1551, HN878, East African
Indian (EAI) (91 0079), Manila (T31), and Indo Oceanic-T17x
(IO-T17x) strains were plated on Middlebrook 7H11 (Difco),
supplemented with OADC. After incubation for 2 weeks at
37 °C, colonies were inoculated into 100 mL of Middlebrook
7H9 supplemented with OADC and 0.05% Tween. After 2 weeks
of growth, cells were thoroughly washed with PBS and used to
inoculate 1 L of GAS media in roller bottles [24]. All cultures
were prepared in triplicate. Culture filtrate was harvested after
two weeks, as previously described [25,26]. Briefly, CFP was
concentrated with a 10 k molecular weight cutoff amicon
ultrafiltration unit and then dialyzed into 10 mM ammonium
bicarbonate. The remaining cell pellets were processed for
RNA isolation.
2.2. Genetic Analysis
The M. tuberculosis rv3804c (ag85A), rv1886c (ag85B), and
rv0129c (ag85C) geneswere PCR-amplifiedwith 50 bp flanking
regions from genomic DNA [27] from the six M. tuberculosis
strains mentioned above. The following primers sets were
used for both generation of the amplicon and subsequent
sequencing: ag85A: (Fwd: 5′-gccgggcccagcgcctgcagtctgacctaattca
gg-3′; Rev: 5′-cccctagcccgtcaggtagctaaccacacggcccg-3′), ag85B:
(Fwd: 5′-ccgcggcggtaaccgatacggaaatgagacg-3′; Rev: 5′-cggctaact
ggctggtgccgtcggctcgcg-3′), and ag85C: (Fwd: 5′-ccgcgatctcgcgctg
cggccacgacattcg-3′; Rev: 5′-ccagtggcgctggcgaaggggtgacc-3′)
(Integrated DNA Technologies). PCR products were gel purified
and sequenced in both directions to determine genetic varia-
tion, if any, between bacterial isolates.
2.3. Quantitative real time PCR (qPCR)
RNA isolation was performed as previously described [28].
cDNA was generated using SuperScript® III First-Strand
Synthesis System (Invitrogen), following the manufacturer
guidelines using 5 μg of total RNA per reaction. Due to
the similarity between the Antigen 85 gene sequences, the
following primers were designed manually to avoid overlap:
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ca-3′), ag85B (L: 5′-aacctgaagttcca ggatgc-3′; R: 5′-cgcctaacgaac
tctgcag-3′) and ag85C (L: 5′-caacggacacttcgacttcc-3′; R: 5′-ttagcgg
atcgcaccgac-3′) (Integrated DNA Technologies). Four dilutions
(100 ng/μL, 10 ng/μL, 1 ng/μL and 0.1 ng/μL) of M. tuberculosis
genomic DNA were used as PCR templates for accurate
generation of standard curves and negative controls. Each
standard dilution and each sample was tested in triplicate
using the following master mix for each reaction: 12.5 μL SYBR
Green, 1 μL Left (L) primer, 1 μL Right (R) primer and 9.5 μL
water. All sampleswere run in three dilutions (10 ng/μL, 1 ng/μL
and 0.1 ng/μL) of cDNA template. Amplifications were per-
formed onan iCycler Thermal Cycler (Bio-rad). The reactionwas
subjected to an initial 55 °C step for 2 min, a denaturation at
95 °C for 2 min followedby 45 cycles of denaturation at 95 °C for
15 s, annealing at 60 °C for 30 s and elongation at 72 °C for 30 s,
followedbyanadditional 5 minat 72 °Cprior to 81 cycles of 10 s
starting at 55 °C and increasing by 0.5 °C each cycle for melt
curve analysis. Standard curves for Ag85A, B and C yielded R
squared values of 0.996, 0.996 and 0.998, respectively.
2.4. One-dimensional and two-dimensional gel
electrophoresis (2DGE)/Western blot analysis
The total protein concentration was determined using a
commercial bicinchoninic acid protein assay kit (Pierce).
One-dimensional protein analysis was performed on 5 μg of
CFP pooled from three biological replicates per strain. Sepa-
ration was performed via 4–12% gradient Bis-Tris gel (Life
Technologies), transferred to nitrocellulose using a transfer
tank (Biorad, Hercules, CA) and standard conditions [29],
blocked with 1% bovine serum albumin in TBST, and probed
with IT-44, a monoclonal anti-Antigen85 complex antibody
(available through BEI resources, Manassas, VA), followed by
probing with an anti-mouse secondary antibody conjugated
to alkaline phosphatase (Sigma) and developed with 5-bromo,
4-chloro, 3-indolylphosphate (BCIP)/nitroblue tetrazolium
(NBT) 1-component phosphatase substrate (KPL).
For the 2DGE, 200 μg of CFP from each isolate was used
for the detection of the Antigen 85 complex. Proteins were
solubilized in 200 μL of rehydration buffer (8 M deionized urea,
1% 3[(3-cholamidopropyl) dimethylammonio]-propanesulfonic
acid (CHAPS)), 1× NuPAGE® Sample Reducing Agent, 0.75%
ZOOM® Ampholytes pH 4–7 and 0.25% ZOOM® Ampholytes
pH 3–10, as previously described [24]. Isoelectric focusing of
samples was performed using ZOOM IPG strips pH 4–7 prior
to reduction with DTT, alkylation with iodoacetamide, and
separation by molecular weight on a NuPAGE Novex 4–12%
Bis-Tris Gel (Life Technologies). Proteins were transferred to
nitrocellulose membranes and Ag85 proteins were probed with
the IT-44 primary antibody and developed as described above.
In-solution digest and mass spectrometry sample preparation
Culture filtrate proteins were digested in-solution as previously
described [30]. 100 μg of each CFP sample was denatured in
6 M guanidine hydrochloride, reduced with 10 mM DTT and
alkylated with 100 mM iodoacetamide. After overnight micro-
dialysis in 10 mM ammonium bicarbonate the samples were
digested with trypsin (1:50, trypsin:lysate) in 10% acetonitrile(ACN) overnight at 37 °C. Digestswere dried and resuspended in
TQ-S loading buffer (TLB) (96.9%water, 3%ACN and 0.1% formic
acid). All digests were performed in deplasticized tubes to
reduce plastic polymer contamination.
2.5. Peptide selection and multiple reaction monitoring
(MRM) development
Skyline (version 1.2.0.3425) was used to build and optimize the
MRM method for the relative and absolute quantification of
peptides [31]. FASTA formatted sequences of the three Antigen
85 complex proteins were used for in silico digestion and
prediction of peptides. Method development included the
peptide parameters set to tryptic digest (KR|P), 0 max missed
cleavages, minimum of 7 amino acids, maximum of 25 amino
acids, excluding peptides containing Met or Cys residues
and the transition settings selecting for precursor charges of 2
and 3, ion charge of 1, monitoring both b and y ions. Resultant
methods were exported to Masslynx (Waters). Collision energy
was predicted and further optimized on each peptide utilizing
Skyline software [32]. Doubly charged precursor ions were
optimized and three transitions (one for quantitation and two
for confirmation) were measured per peptide. All method
development was performed initially on recombinant Ag85A,
Ag85B and Ag85C; final methods were confirmed on trypsin
digested CFP. Final MRM method included the monitoring of a
total of 8 peptides (5unlabeled—Table 1; 3 isotopically labeled—
Table 2), selecting for unique retention times when possible or
dwell times≥ 0.066 s.
2.6. Internal standardization with isotopic peptides in CFP
matrix
For the stable isotope dilution analysis, each labeled peptide
(NewEngland peptide) was resuspended at 200 fmols/μL inTLB.
The peptides were further diluted and combined resulting in
final concentrations of 0.01 fmols/μL, 0.1 fmols/μL, 1 fmols/μL,
10 fmols/μL and 100 fmols/μL of each peptide in TLB spiked
with a Mtb culture filtrate protein matrix (final concentration:
10 ng/μL). One μL of the peptide mixture was injected into a
Xevo TQ-S in triplicate for data acquisition and results
were exported to Skyline for analysis. Upon examination
and standardization of the peaks, the transition results were
exported to excel for calculation of calibration curves (R2
values for each curve are in Table 2), as well as determination
of limits of detection (LODs) and quantitation (LOQ) for each
transition [33,34].
2.7. Multiple reaction monitoring mass spectrometry
All CFP analyses were performed using a LC MS/MS system
which consisted of a Waters nanoACQUITY UPLC coupled to a
Waters TQ-S mass spectrometer fitted with a Trizaic source.
The instrument was operated in positive electrospray ioni-
zation mode using MassLynx V4.1 SCN810 (Waters). Chroma-
tography was performed in randomized triplicate onto a
85 μm × 100 mm Trizaic nanotile packed with BEH C18 1.8 μm.
Peptides were separated using gradient elution with a stable
flow of 0.45 μL/min. The gradient started with 97% buffer A
(99.9% water with 0.1% FA) and 3% buffer B (99.9% ACN with
Table 1 – Five native peptides monitored during the MRM multiplex assay. When possible 2 peptides were monitored per
protein and were chosen and optimized unitizing the aforementioned parameters. If 2 peptides were available, one was
used for quantitation and an additional one for confirmation of the protein. Similarly, for each peptide, three transition ions
were monitored (trapped by the Q3), two of which were used for quantitation and a third for confirmation.
Protein Peptide sequence Rolea MRM transition
(m/za)
Ion type Collision energy Retention time
Q1 Q3
Antigen85a
(Rv3804c)
ALGATPNTGPAPQGA q 661.8386 909.4425 Y10 18 10.21–12.21
q 540.2776 Y6 18
c 372.1878 Y4 18
Antigen85a
(Rv3804c)
FLEGFVR c 434.2398 478.2773 Y4 17 14.29–16.00
c 607.3198 Y5 15
c 720.4039 Y6 16
Antigen85b
(Rv1886c)
NDPTQQIPK c 520.7722 613.3668 Y5 19 8.73–10.73
q 714.4145 Y6 20
q 811.4672 Y7 16
Antigen85c
(Rv0129c)
FLEGLTLR q 474.7793 688.3988 Y6 16 16.00–17.31
q 559.3562 Y5 18
c 502.3348 Y4 12
Antigen85c
(Rv0129c)
WETFLTR c 476.748 766.4094 Y6 22 14.47–16.00
c 637.3668 Y5 16
c 536.3191 Y4 19
a Role: q: quantitation; c: confirmatory.
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was achieved at 30.0 min. Thiswas followedby a linear increase
towards 85% B which was achieved at 32 min and maintained
until 34 min. The system was subsequently switched to 3% B,
which was achieved at 35 min and the column was left to
equilibrate for 10 min. The column was maintained at 46 °C
during analysis, and the samples were kept at 4 °C. TheMSwas
operating in selective reaction mode using electrospray ioniza-
tion inpositive ionmode,with a capillary voltage of 3.4 kVanda
source temperature of 100 °C. Cone voltage was static and the
collision energies were optimized for each compound individ-
ually (See Tables 1 and 2 for parent and product m/z values).
Peak identification was performed using MassLynx software
version 4.1. Calibration curveswere run in triplicate fromwhich
one regression equation was generated. The linear range of the
calibration curve spanned four orders of magnitude for most
transitions (100 amol/μL–100 fmol/μL). The concentration of
each native Antigen 85 peptide was calculated using a spiked
internal standard as a reference. These data are available
through ProteomeXchange with identifier PXD000232.3. Results
3.1. Visualizing differences in secreted Antigen 85
Sparked by initial observations of aberrant Ag85 abundance in
the CFP from an EAI isolate, we set out to compare the
expression pattern of the Antigen 85 complex from six isolates
across four different clades of Mtb. Our analysis included the
well-characterized strains H37Rv and CDC1551 from the
Euro-American lineage, one East African-Indian (EAI) isolate,
the HN878 strain representing the East Asian lineage and the
Manila and T17x strains from the Indo-Oceanic lineage [35].
Biological triplicates of each strain were grown and the CFPwas
analyzed initially by 1D Western blot, followed by 2D analysis(Fig. 1). Due to the high homology between the Antigen 85
proteins (BLAST: identical/positives: A–B: 78%/89%; A–C 67%/
79%; B–C 72%/80%), all available antibodies cross react with all
three proteins in the complex. Consistent with published data,
the Antigen 85 complex displays 2 bands on one-dimensional
SDS-PAGE—with Ag85A (31.65 kD) and Ag85C (32.02 kD)
coupled in one band slightly above the more prominent Ag85B
(30.66 kD) [36]. These proteins were further resolved by isoelec-
tric focusing [14] which further demonstrated the deficiency in
Ag85 abundance in the EAI isolate. Thus, additional quantita-
tive measures were proposed to tease out the differences
between the secretion patterns of the Ag85 complex across the
various isolates and clades ofMtb.
3.2. Antigen 85 transcript analysis
Quantitative PCR analysiswas performed on each of the samples
in an effort to correlate the observed differences in protein
abundance to gene expression. Initially, the level of expression of
Ag85A, B, and C was compared within each strain; no significant
differencewasobservedbetween transcripts (Fig. 2A). In contrast,
several significant differences in mRNA levels were observed
between strains within individual transcripts including an
overall decrease in Ag85B expression in EAI and Manila when
compared to H37Rv, HN878 or IO-T17x and a decrease in
Ag85C expression in Manila when compared to H37Rv, HN878,
and IO-T17x (Fig. 2B). Interestingly, no significant differences
in expression of Ag85A were observed between any of the
strains.
3.3. Multiple reactionmonitoringmass spectrometry analysis
The initial Western blot data from all 18 CFP preparations
provided us with the foundation for visualizing the differences
in total concentration of the secreted Antigen 85 complex from
various isolates. Transcriptomic analysis corroborated our
Table 2 – Three isotopically-labeled peptides monitored during the MRM multiplex assay. One isotopically-labeled peptide
was generated for each of the native proteins beingmonitored. Standard curves were generated for each peptide and native
peptides were quantified based on these curves. The LOD and LOQ values were used to determine the concentration of CFP
injected during the analysis, so that the proteins being monitored were above the LOQ for quantitation and above the LOD
for confirmation.
Protein Peptide sequence MRM transition
(m/za)
Ion type R2 LOD (CV%) LOQ (CV%)
Q1 Q3
Antigen 85a
(Rv3804c)
ALGATPNTGP^APQGA 664.8455 915.4563 Y10 0.998 4.99 16.66
546.2914 Y6 0.997 5.7 18.99
372.1878 Y4 0.998 5.08 16.9
Antigen 85b
(Rv1886c)
NDPTQQIPK^ 524.7793 819.4814 Y7 0.998 5.06 16.87
722.4287 Y6 0.998 5.14 17.16
621.381 Y5 0.998 4.94 16.48
Antigen 85c
(Rv0129c)
FLEGLTLR^ 479.7834 698.4071 Y6 0.998 12.8 42.7
569.3645 Y5 0.998 12.66 42.2
512.343 Y4 0.998 12.7 42.36
P^ = Proline (U13C5, 15 N); K^ = Lysine (U-13C6, 15 N2); R^ = Arginine (U-13C6, 15 N4).
LOD ≥ (3 * sd of Y)/slope, LOQ ≥ (10 * sd of Y)/slope and are both expressed in fM.
a Only doubly charged peptides were monitored.
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Manila and partially explained observations of reduced Ag85
complex in EAI. We developed a multiplexed proteomic assay
for the absolute quantitation of the three Antigen 85 proteins in
order to better define the differences observed in protein
abundance and to determine whether qPCR or Western blot
analysis was more representative of the quantities of Ag85
protein in each strain. By coupling this tool with isotopicallyFig. 1 – Relative Quantification of total Ag85 complex in CFP
viaWestern blot. Left: 1D analysis of CFP pooled from three
biological replicates of each isolate. Center: 2D analysis of
CFP froma single representative biological replicate per strain.
BothWestern blots were probed using the IT-44 mouse
monoclonal antibody against theAg85 complex. Right: ImageJ
Software was used for densitometry analysis using all three
biological replicates from 1D and 2D gel for the comparison.
Variation between the biological replicates is indicated by
the error bars. Significance: * indicates P < 0.01 between
H37Rv and EAI, while ** indicates P < 0.05 between H37Rv
and Manila.labeled peptide standards (Fig. 3), we were able to achieve
limits of detection (LODs) and quantitation (LOQ) in the low
femtomolar range (Table 2), allowing facile quantification of
all three proteins in the CFP without any enrichment or
fractionation.
A comparison of the quantity of each individual protein
demonstrated significant differences in the ratio of each
protein within each strain (t-test values: A vs B: P < 0.0001, A
vs C: P = 0.015, and B vs C, P < 0.0001). This is in contrast to
the qPCR data, which demonstrated average ratios of 1:1:1 for
Ag85 A, B, and C within each strain (Fig. 2A). In addition, the
published protein ratio of 2:3:1 (A:B:C) initially reported inMtb
based on analysis the Erdman strain secreted fraction by
SDS-PAGE [37] was not observed in any of the strains tested.
Instead, absolute quantification of protein abundance by
MRM analysis demonstrated that ratios of protein quantities
were conserved within clades or were more similar among
more closely related strains. Specifically, strain H37Rv and
CDC1551 presented with a ratio of 5:13:1 (Ag85 A:B:C),
whereas HN878 (East Asian) and EAI (East Asian Indian)
presented with a ratio of 1:8:1 and Manila and IO-T17x (both
Indo-Oceanic clades) presented with a ratio of 2:7:1 (Fig. 4).
Despite the conservation in ratios observed among strains,
there was no relationship between the total amount of
Antigen 85 complex among strains, with quantities ranging
from 0.68 (Manila) to 1.30 fM (IO-T17x) per ng of CFP, due
largely to the difference in Ag85B abundance between these
two strains (Table 3). Oddly, these two isolates are both from
the Indo-Oceanic lineage and highlight the extreme deviation
in synthesis of this complex (while the overall ratios of the
components are conserved). Finally, the MRM results for total
Ag85 complex are consistent with the quantity of protein
detected for EAI andManila byWestern blot (Fig. 1), but do not
correlate with the Western blot data for IO-T17x, indicating
additional Ag85 complex in IO-T17x that may not be reliably
detected by the monoclonal antibody used.
When each Ag85 protein was queried for significant dif-
ferences between strains, no correlation between individual
Fig. 2 – Comparative Quantification of Antigen 85 complex transcripts by qPCR. The average ng of Antigen 85 A, B, and CmRNA
transcripts over 3 biological, 3 technical reps for each strainwas calculated based on the calibration curves for each transcript.
Despite the known differences in protein ratios, the mRNA levels for Antigen 85A, B, and C are comparable, P > 0.05 (A);
however, there are several significant differences between strains within each transcript (B), including H37Rv vs EAI and
Manila: P < 0.001, HN878 vs EAI and Manila: P < 0.001, IO-T17x vs EAI and Manila: P < 0.001 for Ag85B; Manila vs IO-T17x,
HN878, and H37Rv: P < 0.001 for Ag85C.
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Specifically, Ag85 A and C demonstrated significant differences
(P < 0.05) for all comparisons, with the exception of H37Rv and
Manila, HN878, Manila and HN878, and IO-T17x and CDC1551
for Ag85C and H37Rv and IO-T17x, CDC1551, HN878 and EAI,
andCDC1551and IO-T17x for Ag85A. In contrast, fewsignificant
differences were reported for Ag85B, with only Manila and
IO-T17x and HN878, and IO-T17x and EAI demonstrating
significant differences in quantities between strains (P < 0.01).
The lack of significant differences in Ag85B quantity is likely
due to the variability in abundance observed within biological
replicates (Table 3).
3.4. Alterations of the Mtb secretome
Since transcript levels for the Antigen 85 complex were not
significantly different and thus could not explain differences inFig. 3 – Scheduled Multiplexed MRM Method. A representative to
total of eight peptides—the five native peptides (from the threem
residue in red) are shown. The area of each peak is the additive
maximum of six ions being acquired at any point based on 2 miprotein abundance, changes in protein transport or processing
was explored in an effort to explain the downstream variation
of these proteins in the culture filtrate. MRM assays were
performed on whole cell lysate (WCL) preparations to quantify
these proteins in the cell. All peptides were normalized based
on adjusted calibration curves, which account for the increased
complexity of the WCL matrix. This analysis revealed low
(attomolar) levels of Ag85 complex in the WCL, with no
detectable quantitative differences. To clarify the source of
secreted Antigen 85 complex reduction for Manila and EAI
and pinpoint whether this is due to an overall secretion
deficiency or if this is an Antigen 85 complex specific
phenomenon, the total protein yield of culture filtrate was
compared. This revealed several significant differences
between the overall concentrations of secreted proteins
(Fig. 5), with the total secreted protein level from EAI culture
filtrates only half that of H37Rv. A similar trend wastal ion chromatogram of a multiplex run which monitors a
embers of the complex) and three isotopically labeled (labeled
product of all three transition ions per peptide, with a
n scheduled windows flanking the retention time.
Fig. 4 – Absolute Quantification of Antigen 85 complex
components by MRM. Plot of average quantity of Antigen 85
A, B, and C peptides over 3 biological, 3 technical replicates
for each strain. One fM of each isotope-labeled peptide
standard was spiked into the trypsin digested CFP. Native
peptides were normalized against a standard curve
generated with each labeled peptide.
Fig. 5 – Comparison of total CFP Concentration. The overall
yield of secreted proteinswas calculated by BCA and shows a
significant decrease in EAI. * indicates P < 0.05 between
H37Rv and EAI. Additional significance: P < 0.01 between
both EAI and Manila when compared to IO-T17x.
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hypothesize that the disparity in overall CFP yield is due to
either inefficient export or translation in the EAI and Manila
strains.
All three Antigen 85 proteins contain N-terminal signal
sequences and are transported via SecA1 followed by cleavage
of the leader peptide by the type I signal peptidase I, LepB
[38,39]. To determine if Sec dependent transport was altered
between strains, several proteins–both SecA1 dependent
(Mpt32 and PhoS1/PstS1) and SecA2 dependent (SodA and
KatG)–were monitored by Western blotting (data not shown).
Secretion of the all four proteins appeared stable across all
biological replicates and isolates. To confirm this finding and
reveal other significant differences, a shotgun proteomic
analysis of the CFP utilizing data-dependent acquisition on a
linear ion trap (LTQ) mass spectrometer was used to look at
trends in relative quantitation of all secreted proteins. Despite
the amount of protein digested (20 μg) and subsequent peptide
concentration (200 ng/μL) injected into the mass spectrometer
being equivalent for each sample, the resultant spectral counts
and proteins identified were significantly lower in strain EAI vs
the other strains. This trend did not appear specific to Sec
secreted proteins or correlate with the presence/absence of a
signal peptide. Irrespective of themechanism, it is clear that the
EAI is compromised in its ability to secrete most proteins—oneTable 3 – Absolute Quantification of Antigen 85 complex components by MRM. This table summarizes the average amount
of each protein extrapolated from calibration curves generated by isotopically labeled peptides in a CFP matrix.
Strain Ag85A Ag85B Ag85C Total Complex
fM per ng of CFP sd fM per ng of CFP sd fM per ng of CFP sd fM per ng of CFP sd
H37Rv 0.23 0.03 0.61 0.07 0.08 0.01 0.93 0.02
CDC1551 0.28 0.03 0.71 0.06 0.1 0.01 1.09 0.02
HN878 0.1 0.01 0.86 0.08 0.08 0.01 1.04 0.03
EAI 0.09 0.01 0.64 0.08 0.08 0.01 0.81 0.03
Manila 0.13 0.02 0.47 0.06 0.08 0.01 0.68 0.02
IO-T17x 0.27 0.02 0.91 0.07 0.12 0.01 1.3 0.03exception appears to be proteins related to esx secretion (data
not shown).4. Discussion and conclusions
Themain objective of this study was to apply a proteomic and
genomic work flow to understand discrepancies between
Antigen 85 expression or secretion across various lineages of
Mtb. From the initial observation of decreased Antigen 85
complex abundance in the culture filtrate to the full quanti-
tative description across six isolates representing four clades,
we have clearly demonstrated variability in Ag85B expression
and secretion, and to a lesser extent Ag85A secretion, not only
across lineages, but within subclades as well. Quantitative
comparison of these dominant mycobacterial antigens from
isolates of various clades can shed light on geographical
differences relevant to optimal vaccine and diagnostic design,
and demonstrates the utility of MRM-MS for peptide quanti-
fication in Mtb (more commonly used for quantifying small
molecules) and for phylogenetic comparisons. As shown here
by ourselves and by our colleagues [40], benefits include an
increased specificity, as compared to either western blotting
or an untargetedmass spectrometry analysis, which is critical
during quantitation when distinguishing between highly
homologous proteins. With protein sequence identities rang-
ing from 67–78% between the Ag85 components, antibodies
148 J O U R N A L O F P R O T E O M I C S 9 7 ( 2 0 1 4 ) 1 4 1 – 1 5 0have strong cross-reactivity and shotgun proteomics often
fails in differentiating between similar peptides. MRM assays
remove the ambiguity from quantitative analyses. We have
shown the ability to quantify not only highly secreted proteins
(Ag85A and Ag85B), but also low abundance proteins (Ag85C),
reliably and reproducibly detecting these peptides in the high
attomolar to low femtomolar range. This technique has
allowed us to tease apart differences originally identified by
2D-westerns, giving definition to the shift in the pattern of
Ag85 complex components. Based on our MRM data, it is clear
that the flux in Ag85 complex can be attributed primarily to
variability in Ag85B expression and secretion and to a lesser
extent Ag85A secretion. The amount of Ag85C in the CFP was
highly conserved throughout the samples, which correlates
with previous reports of strict regulation of this protein [28].
One aspect which MRM assays fail to address is protein
speciation [41,42]. It is clear from our 2D-western analysis, as
well as previously published 2D gel studies [43], that multiple
protein species of each protein contribute to the complex
patterns shown in Fig. 1. MALDI-ToF analysis of each purified,
intact native Ag85 protein did not demonstrate different
molecular masses indicative of post-translational modifica-
tions that result in significant mass changes (our unpublished
data). One explanation could be that the protein species
observed by 2D gels are the result of deamidation of Asn and
Gln, or other small mass post-translational modifications
which would result in the observation of multiple protein
species by gel electrophoresis and mass differences that are
difficult to resolve when large polypeptides (i.e. greater than
10,000 AMU) are analyzed by MALDI-ToF mass spectrometry.
These differences may affect the MRM assay results (due to
low, even 1–2 AMU mass shifts). Every effort was made to
optimize the MRM assays to identify only those peptides that
do not appear to undergo deamidation, or be otherwise
modified in the native organism; additional peptides were
also quantitatively monitored to confirm protein abundance
whenever possible. Nonetheless, modifications resulting in
small mass changes of targeted peptides is still plausible, and
variability in the quantitation of the monitored peptides as a
result of such amodification or cleavage variants, would not be
identified by our MRM analysis and thereby skew the results.
These changes could still be very telling as to functionality and
antigenicity of the protein and should be pursued if such
modifications are subsequently found.
Structurally, the three proteins are very similar with
identical catalytic active sites, two exceptions being the
loose conformation in the C-terminal region and lack of a
disulfide bond in the β-parallel sheet of Ag85C [16,17]. The
majority of variation between these three proteins resides
within the amino acids located at the C-terminus. This
attribute was exploited for our MRM assays, as all three of
the peptides monitored in the assays were designed from the
latter half of the protein. All three components are exported
through a SecA dependent pathway and undergo proteolytic
cleavage of their leader sequencesby the type I signal peptidase,
LepB [39]. However, no other posttranslational modifications
(such as glycosylation) have been shown [37]. The exact
mechanism for retention in the cell wall vs full secretion has
not been identified. Additionally, there is no evident variation in
the coding regions of the antigen 85 complex genes betweenclades. Despite these consistencies, variations in both tran-
scription and translationwere observed. Specifically, regulation
of transcription ofAg85 A andC appeared similar across strains,
whereas Ag85B expression did not appear to be a conserved,
regulated event. Antigen 85C appears to be additionally
controlled at the protein level, given the low variability in
protein quantity foundacross lineages. This control seems to be
both a translational and secretion event due to the consistently
low abundance of this protein in any sample, and its exclusive
presence in the culture filtrate.
The four lineages of Mtb used in this analysis are not
evenly distributed in the global population, but are linked
geographically, with the highest burden represented by
lineage 1 (Indo-Oceanic)—primarily in East and Southeast
Asia and India; followed by lineages 2 and 3 (East Asian and
EAI) [35]. Unfortunately, the best characterized strains (by
genomic sequencing) and the most common isolates used for
basic research, as well as vaccine challenge in animal models,
are predominantly from lineage 4 (Euro-American). While the
distribution of this clade is more ubiquitous, the overall
burden of disease is lowest [35]. From the aforementioned
observations, we can infer that the variable Antigen 85
complex secretion pattern detected in each clade is as skewed
during the human infection. Differences in protein expression
between clades may affect the efficacy of diagnostic reagents
designed to recognize specific antigens in a clinical sample,
unless packaged as part of a multiplex or multi-marker based
assay. Similar losses in efficacy may be found when vaccines
tailored to present specific Mtb proteins and elicit clonal cell
mediated immune responses are administered in regions
where certain clades with poor antigen accessibility domi-
nate. This idea is consistent with published variation in BCG
efficacy based on the origin of the strain of BCG used to
prepare the vaccine. BCG expresses Antigen 85 complex [44],
however notable differences between the BCG Moreau and
BCG Pasteur CFP, including Ag85B abundance, have been
described and may contribute to the variance in efficacy [45].
This is in contrast to vaccines engineered to bolster global
innate and adaptive immunity, where discreet differences in
specific protein abundance may be less problematic. Indeed,
vaccines designed to block early infection events by way of
stimulating and maintaining sentinel immune responses
(e.g. via activation of specific B, mucosal-associated invariant
T (MAIT) and/or γδ T cells) have become increasingly
attractive as part of an innovative approach to tuberculosis
vaccine design [20].Acknowledgements
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